Research Article| Volume 38, ISSUE 8, P1845-1857, August 2016

Pharmacokinetic Interaction Between Rosuvastatin, Telmisartan, and Amlodipine in Healthy Male Korean Subjects: A Randomized, Open-label, Multiple-dose, 2-period Crossover Study



      Rosuvastatin, a hydroxy methylglutaryl coenzyme A reductase inhibitor; telmisartan, an angiotensin receptor blocker; and amlodipine, a calcium channel inhibitor, are commonly prescribed together for the treatment of hypertension nonresponsive to monotherapy and accompanied by dyslipidemia. However, the pharmacokinetic interactions among these 3 substances are not well understood. The aim of this study was to investigate the pharmacokinetic drug–drug interactions among rosuvastatin, telmisartan, and amlodipine in a healthy Korean male population.


      In both parts of this randomized, open-label, multiple-dose, 2-part, 2-period crossover study, subjects aged 19 to 55 years were enrolled. In part 1, each subject received rosuvastatin 20 mg with and without 2 fixed-dose combination (FDC) tablets of telmisartan/amlodipine 40/5 mg, once daily for 9 consecutive days. In part 2, each subject received 2 FDC tablets of telmisartan/amlodipine 40/5 mg with and without rosuvastatin 20 mg, once daily for 9 consecutive days. In both parts, there was a 13-day washout period between treatments. Pharmacokinetic samples were collected up to 72 hours after the last dose in subjects who received rosuvastatin only, and up to 144 hours after the last dose in subjects who received telmisartan/amlodipine with or without rosuvastatin. Adverse events (AEs) were assessed via interviews and physical examinations.


      Forty-eight subjects were enrolled, of whom 19 in part 1 and 22 in part 2 completed the study. In Part 1, the 90% CIs of the geometric mean ratios (GMRs) (coadministration of rosuvastatin and telmisartan/amlodipine to monotherapy with rosuvastatin) of the primary pharmacokinetic parameters (AUCτ and Cmax,ss) were: rosuvastatin, 1.1436 to 1.3059 and 1.8970 to 2.3514, respectively; and N-desmethyl rosuvastatin, 0.8441 to 1.0200 and 1.1971 to 1.5457. In part 2, the 90% CIs of the GMRs (coadministration to monotherapy with telmisartan/amlodipine) were: telmisartan, 1.1204 to 1.4228 and 0.9940 to 1.5940; amlodipine, 0.9705 to 1.0636 and 0.9813 to 1.0779. There were no significant differences in the prevalences of AEs between the treatments, and all reported AEs were mild or moderate.


      These results demonstrate that when rosuvastatin, telmisartan, and amlodipine are coadministered to healthy male subjects, pharmacokinetic exposure increases with respect to rosuvastatin and telmisartan, whereas no change occurs with respect to amlodipine. However, based on previous analyses, the degree of increase in the exposure observed was not regarded as clinically significant. All treatments were well-tolerated.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Liao J.K.
        Endothelium and acute coronary syndromes.
        Clin Chem. 1998; 44: 1799-1808
        • Rosenson R.S.
        Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia.
        Expert Rev Cardiovasc Ther. 2003; 1: 495-505
        • Olsson A.G.
        • McTaggart F.
        • Raza A.
        Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.
        Cardiovasc Drug Rev. 2002; 20: 303-328
      1. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization/International Society of Hypertension Statement on Management of Hypertension. 2003.

      2. Boehringer Ingelheim. Micardis (telmisartan) [prescribing information]. Accessed November 3, 2015.

        • Battershill A.J.
        • Scott L.J.
        Telmisartan: a review of its use in the management of hypertension.
        Drugs. 2006; 66: 51-83
        • Ferdinand K.C.
        • Kleinpeter M.A.
        Management of hypertension and dyslipidemia.
        Curr Hypertens Rep. 2006; 8: 489-496
        • Ansell B.J.
        Evidence for a combined approach to the management of hypertension and dyslipidemia.
        Am J Hypertens. 2005; 18: 1249-1257
        • Jackson R.
        • Lawes C.M.
        • Bennett D.A.
        • Milne R.J.
        • Rodgers A.
        Treatment with drugs to lower blood pressure and blood cholesterol based on an individual׳s absolute cardiovascular risk.
        Lancet. 2005; 365: 434-441
        • Hua W.J.
        • Hua W.X.
        • Fang H.J.
        The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.
        Cardiovasc Ther. 2012; 30: e234-e241
        • Kitamura S.
        • Maeda K.
        • Wang Y.
        • Sugiyama Y.
        Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
        Drug Metab Dispos. 2008; 36: 2014-2023
        • Kock K.
        • Brouwer K.L.
        A perspective on efflux transport proteins in the liver.
        Clin Pharmacol Ther. 2012; 92: 599-612
        • Niemi M.
        • Pasanen M.K.
        • Neuvonen P.J.
        Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.
        Pharmacol Rev. 2011; 63: 157-181
      3. AstraZeneca. Crestor (rosuvastatin) [prescribing information]. Accessed November 3, 2015.

      4. Crestor tablets. AccessdataFDA. Accessed June 3, 2016.

        • Ishiguro N.
        • Maeda K.
        • Kishimoto W.
        • et al.
        Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans.
        Drug Metab Dispos. 2006; 34: 1109-1115
        • Ishiguro N.
        • Maeda K.
        • Saito A.
        • et al.
        Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide.
        Drug Metab Dispos. 2008; 36: 796-805
        • Miura M.
        • Satoh S.
        • Inoue K.
        • et al.
        Telmisartan pharmacokinetics in Japanese renal transplant recipients.
        Clin Chim Acta. 2009; 399: 83-87
      5. Boehringer Ingelheim. Twynsta (telmisartan/amlodipine) [prescribing information]. Accessed November 3, 2015.

        • Abernethy D.R.
        Pharmacokinetics and pharmacodynamics of amlodipine.
        Cardiology. 1992; 80: 31-36
        • Nishio S.
        • Watanabe H.
        • Kosuge K.
        • et al.
        Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension.
        Hypertens Res. 2005; 28: 223-227
        • Park C.G.
        • Lee H.
        • Choi J.W.
        • et al.
        Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin.
        Int J Clin Pharmacol Ther. 2010; 48: 497-503
        • Son H.
        • Lee D.
        • Lim L.A.
        • et al.
        Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine.
        Drug Metab Pharmacokinet. 2014; 29: 120-128
        • Zhou Y.T.
        • Yu L.S.
        • Zeng S.
        • et al.
        Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.
        Ther Clin Risk Manag. 2014; 10: 17-26
        • Son M.
        • Kim Y.
        • Lee D.
        • et al.
        Pharmacokinetic interaction between rosuvastatin and telmisartan in healthy Korean male volunteers: a randomized, open-label, two-period, crossover, multiple-dose study.
        Clin Ther. 2014; 36: 1147-1158
      6. Clinical Pharmacology And Biopharmaceutics Review(s) Application Number 22-401. Accessed December 23, 2015.

        • Stangier J.
        • Su C.A.
        Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers.
        J Clin Pharmacol. 2000; 40: 1347-1354
      7. Ministry of Food and Drug Safety. Korean Good Clinical Practice Guideline. 2014.
      8. World Medical Association. Declaration Of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Accessed November 3, 2015.

      9. Center for Drug Evaluation and Research (CDER), Food and Drug Administration, US Dept of Health and Human Services. Guidance for Industry Drug Interaction Studies: Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Accessed June 3, 2016.

        • Yang J.
        • Li L.J.
        • Wang K.
        • et al.
        Race differences: modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients.
        Acta Pharmacol Sin. 2011; 32: 116-125
        • Stangier J.
        • Su C.A.
        • van Heiningen P.N.
        • et al.
        Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge.
        J Cardiovasc Pharmacol. 2001; 38: 672-685
        • Bhad P.
        • Ayalasomayajula S.
        • Karan R.
        • et al.
        Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension.
        J Clin Pharmacol. 2011; 51: 933-942
      10. Clinical Pharmacology and Biopharmaceutics Review(S) Application Number 200175. Accessed December 30, 2015.

        • Stangier J.
        • Su C.A.
        • Roth W.
        Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients.
        J Int Med Res. 2000; 28: 149-167
        • Abad-Santos F.
        • Novalbos J.
        • Galvez-Mugica M.A.
        • et al.
        Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study.
        Pharmacol Res. 2005; 51: 445-452